Seek Returns logo

BMRN vs. MRNA: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at BMRN and MRNA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolBMRNMRNA
Company NameBioMarin Pharmaceutical Inc.Moderna, Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryBiotechnologyBiotechnology
Market Capitalization10.50 billion USD9.70 billion USD
ExchangeNasdaqGSNasdaqGS
Listing DateJuly 26, 1999December 7, 2018
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of BMRN and MRNA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

BMRN vs. MRNA: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolBMRNMRNA
5-Day Price Return3.91%0.04%
13-Week Price Return-4.88%-11.60%
26-Week Price Return-8.45%-2.82%
52-Week Price Return-17.90%-41.22%
Month-to-Date Return2.17%-8.80%
Year-to-Date Return-16.74%-40.43%
10-Day Avg. Volume2.36M11.56M
3-Month Avg. Volume2.29M10.45M
3-Month Volatility26.60%59.86%
Beta0.271.20

Profitability

Return on Equity (TTM)

BMRN

8.84%

Biotechnology Industry

Max
96.19%
Q3
12.45%
Median
-16.39%
Q1
-47.43%
Min
-131.19%

BMRN’s Return on Equity of 8.84% is on par with the norm for the Biotechnology industry, indicating its profitability relative to shareholder equity is typical for the sector.

MRNA

-31.40%

Biotechnology Industry

Max
96.19%
Q3
12.45%
Median
-16.39%
Q1
-47.43%
Min
-131.19%

MRNA has a negative Return on Equity of -31.40%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

BMRN vs. MRNA: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

BMRN

16.82%

Biotechnology Industry

Max
84.13%
Q3
19.34%
Median
-1.39%
Q1
-117.64%
Min
-296.77%

BMRN’s Net Profit Margin of 16.82% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

MRNA

-139.61%

Biotechnology Industry

Max
84.13%
Q3
19.34%
Median
-1.39%
Q1
-117.64%
Min
-296.77%

MRNA has a negative Net Profit Margin of -139.61%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

BMRN vs. MRNA: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

BMRN

19.89%

Biotechnology Industry

Max
78.85%
Q3
20.86%
Median
0.51%
Q1
-128.29%
Min
-315.84%

BMRN’s Operating Profit Margin of 19.89% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

MRNA

-155.15%

Biotechnology Industry

Max
78.85%
Q3
20.86%
Median
0.51%
Q1
-128.29%
Min
-315.84%

MRNA has a negative Operating Profit Margin of -155.15%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

BMRN vs. MRNA: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

SymbolBMRNMRNA
Return on Equity (TTM)8.84%-31.40%
Return on Assets (TTM)7.13%-24.44%
Net Profit Margin (TTM)16.82%-139.61%
Operating Profit Margin (TTM)19.89%-155.15%
Gross Profit Margin (TTM)81.32%63.49%

Financial Strength

Current Ratio (MRQ)

BMRN

4.83

Biotechnology Industry

Max
15.83
Q3
7.97
Median
4.06
Q1
2.64
Min
0.72

BMRN’s Current Ratio of 4.83 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

MRNA

3.93

Biotechnology Industry

Max
15.83
Q3
7.97
Median
4.06
Q1
2.64
Min
0.72

MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

BMRN vs. MRNA: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

BMRN

0.10

Biotechnology Industry

Max
1.27
Q3
0.62
Median
0.13
Q1
0.00
Min
0.00

BMRN’s Debt-to-Equity Ratio of 0.10 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

MRNA

0.01

Biotechnology Industry

Max
1.27
Q3
0.62
Median
0.13
Q1
0.00
Min
0.00

MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

BMRN vs. MRNA: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

BMRN

-21.18

Biotechnology Industry

Max
72.37
Q3
1.71
Median
-15.18
Q1
-65.75
Min
-166.46

BMRN has a negative Interest Coverage Ratio of -21.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

MRNA

--

Biotechnology Industry

Max
72.37
Q3
1.71
Median
-15.18
Q1
-65.75
Min
-166.46

Interest Coverage Ratio data for MRNA is currently unavailable.

BMRN vs. MRNA: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

SymbolBMRNMRNA
Current Ratio (MRQ)4.833.93
Quick Ratio (MRQ)3.103.40
Debt-to-Equity Ratio (MRQ)0.100.01
Interest Coverage Ratio (TTM)-21.18--

Growth

Revenue Growth

BMRN vs. MRNA: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

BMRN vs. MRNA: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

BMRN

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BMRN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

MRNA

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

BMRN vs. MRNA: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

BMRN

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BMRN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

MRNA

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

BMRN vs. MRNA: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

SymbolBMRNMRNA
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

BMRN

20.17

Biotechnology Industry

Max
115.91
Q3
56.76
Median
21.80
Q1
15.79
Min
4.51

BMRN’s P/E Ratio of 20.17 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

MRNA

--

Biotechnology Industry

Max
115.91
Q3
56.76
Median
21.80
Q1
15.79
Min
4.51

P/E Ratio data for MRNA is currently unavailable.

BMRN vs. MRNA: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

BMRN

3.39

Biotechnology Industry

Max
58.56
Q3
29.31
Median
8.30
Q1
4.89
Min
0.86

In the lower quartile for the Biotechnology industry, BMRN’s P/S Ratio of 3.39 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

MRNA

4.30

Biotechnology Industry

Max
58.56
Q3
29.31
Median
8.30
Q1
4.89
Min
0.86

In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 4.30 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

BMRN vs. MRNA: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

BMRN

1.72

Biotechnology Industry

Max
17.92
Q3
10.38
Median
4.78
Q1
2.85
Min
0.78

BMRN’s P/B Ratio of 1.72 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

MRNA

1.08

Biotechnology Industry

Max
17.92
Q3
10.38
Median
4.78
Q1
2.85
Min
0.78

MRNA’s P/B Ratio of 1.08 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

BMRN vs. MRNA: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

SymbolBMRNMRNA
Price-to-Earnings Ratio (TTM)20.17--
Price-to-Sales Ratio (TTM)3.394.30
Price-to-Book Ratio (MRQ)1.721.08
Price-to-Free Cash Flow Ratio (TTM)12.7131.69